Houston experts at SXSW: Why now is the opportune time for space commercialization

Houston House

Houston's primed to lead space innovation into the future — it's already happening here, as one panel at SXSW explains. Image via axiomspace.com

For all of the time they've been on earth, humans have looked up and wondered what was out there. Now more than ever, as a recent panel of experts discussed, humans are equipped to find out.

“We actually have, for the very first time, not just the ability to answer those questions, but to be able to go and live among the stars,” says Douglas Terrier, associate director for vision and strategy at NASA's Johnson Space Center. “It’s really a phenomenal thing to think that we are existing at this time.”

Terrier was joined by fellow panelists Matt Ondler, CTO of Axiom Space, and Tim Crain, CTO of Intuitive Machines, along with moderator Arturo Machuca, director of Houston Spaceport, to explore what has contributed to this unique moment in time for space commercialization. The panel, which was presented by Houston Spaceport and hosted by the Greater Houston Partnership, took place at Houston House at SXSW on Sunday, March 13.

An industry that was run exclusively by the government has evolved to include commercialization — and not just on a corporate level.

“We’re at this inflection point where access to space is easier — companies are emerging and it’s not just NASA and big companies like Boeing and Lockheed that can participate in space,” Ondler says.

This evolution was crucial to continue developing the technologies needed to advance the industry. Ondler's company Axiom Space is working on the first commercial space station for lower earth orbit, or LEO. This project will be 100 to 1,000 times less expensive than what it cost to build the International Space Station.

“We’re really leveraging so much history and so much of the government’s investment to build our commercial space station,” Ondler says.

The LEO economy is a trillion dollar economy — and one that has been overtaken by commercial companies, which is exactly what NASA needed to allow for it to refocus efforts to returning to the moon with its Artemis project.

“We’ve gotten over that first obstacle where we’ve commercialized operations of low earth orbit,” Terrier says. “That frees us up to look further.”

For decades, the aerospace industry has been responsible for churning out technologies that, in addition to their space application, can make a difference on earth as well.

“We spend a lot of money getting to space, but what it does is push forward all of these things we have to invent, and they find their ways into application in medicine, water purification, clean energy — all return tenfold value to our society," Terrier says on the panel.

Today, Terrier says the space economy is over $400 billion — and only a quarter of that is government investment. With this influx of companies working in space innovation, Houston has all it needs to be a leader in the field.

“Innovation and the ability to commercially engage in space requires a lot of ideas and new ways of looking of things,” Crain says, pointing out the area around the JSC and the spaceport. “The more opportunities we have for these ideas to come together and interchange, that is going to open up the capability to make commercialization successful.”

He continues saying the city is building a critical mass with space tech startups, talent within engineering and manufacturing, government support, and more.

“It’s more open now than it's ever been for both the city and for NASA to support companies who want to work in Houston,” Crain says. “When you put all those ingredients together the opportunities are really endless, and it’s the place to be.”

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New CEO brings strategic vision to Houston co. advancing neurodegenerative disease treatments

Q&A

Coya Therapeutics has named a new CEO. As of Nov. 1, Arun Swaminathan replaced Co-founder Howard Berman in the role. Berman has assumed the title of executive chairman, in which he will still remain active with the company.

Swaminathan started with Coya two years ago as chief business officer. This transition was planned, says the PhD-holding scientist and businessman.

“(Berman's) intent was that it was the right time to put in place a CEO that, as we move into the operational phases of the company, that can take the reins from him,” he tells InnovationMap.

Coya Therapeutics is a publicly traded biotechnology company that is working on two novel treatments for Alzheimer's disease. Coya's therapeutics, which are currently in trials, use regulatory T cells (T regs) to target both systemic- and neuroinflammation in patients.

InnovationMap: Berman has been a very visible CEO. Will you follow suit?

Arun Swaminathan: I think it's part of the CEO’s job to be visible and to communicate the value of our company to all the stakeholders out there. So yes, I do plan to be visible as well. Obviously, Howard as the founder had elements that he talked about, the foundational stories. I obviously will be doing less of that.

IM: What was your journey from the lab to the boardroom?

AS: I have a PhD from the University of Pittsburgh. I like to say that I grew up at Bristol Myers Squibb, so I started in a clinical pharmacology group at BMS, running clinical trials, but in the cardiovascular and metabolic space.

What happened was, as I was the study director on a diabetes trial there, and the data starts coming in for these early diabetic trials, and I got highly involved with the commercial folks at BMS in starting to plan out “What does the target profile look like? How is this going to play out in the real world?” You know, the marketing teams and commercial teams start engaging when clinical data is available, because they're starting to plan for the eventual launch of the product.

That gave me a lot of exposure to the commercial side of things, and I also got a lot of experience presenting to opinion leaders and others through that role. And I said, “What I really love is that intersection between science and business.” And so I think that was my moment.

Then I moved to business development and licensing, where I helped scan the universe for assets and talk to CEOs of companies like Coya as a junior person, trying to understand if there's something that we can bring into BMS to strengthen the pipeline of BMS. So that gave me exposure to deals, how deals are structured, how you negotiate a lot of that kind of stuff.

Then I said, “Look, if I want to be a complete person in biotech, I do need to go into more true commercial roles.” So I went into commercial strategy. I was involved in the commercial strategy for what is now known as Eliquis. Was back then known as apixaban. That’s still the generic name.

Then I led marketing for Orencia, a rheumatoid arthritis drug. So I went and got both strategic and tactical marketing experience at BMS, and then I used all of that experience, rounded up. I eventually ended up co-founding a company, and that's led me to the last nine years with smaller biotech companies. So that's my evolution and path. But I think my true moment of realization was about three years into my clinical role at BMS, when I said, what I really enjoy is translating good science into commercial value, and I think that's what excites me.

IM: Why is Houston an important part of Coya's success?

AS: It is important that Coya stays in Houston, because we have a very close association with Houston Methodist, we get a lot of our work, our early research work still done through Houston Methodist, through Dr. [Stanley] Appel's lab and through other experts. We absolutely have a special research agreement with Houston Methodist, so we have a very strong reason to be in Houston. So, we do not anticipate moving out of Houston.

------

This conversation has been edited for brevity and clarity.

California femtech leader integrates Houston-founded conversational AI tool

girl gang

Willow users, meet Ema — you're new best AI-enabled friend.

Houston-founded Ema (née SocialMama), an AI resource for maternal health support, has been loaded onto the Willow Innovations Inc. app, a platform for breastfeeding mothers.

"We are thrilled to integrate our conversational AI platform into the Willow App and leverage the power of advanced technology to meet women where they are with the information they need," Amanda Ducach, founder of Ema, says in a news release. "Ema and Willow have a shared mission to make lasting improvements in women's health and we built a one-of-a-kind solution that addresses the unique challenges mothers face regularly.

"Our partnership represents a critical advancement for today's mothers and demonstrates how responsible AI can improve the maternal care experience," she continues.

Now, users on the app can utilize Ema's HIPPA-secure tool that pulls from a comprehensive, proprietary database of expert-backed information. The conversational AI chatbot responds prioritizing speed, accuracy, and empathy and compassion for users. Ema reports that their users "will feel like they are talking with their favorite postpartum (labor and delivery) nurse."

"New moms don't have enough support — for their feeding and parenting journey, or in their postpartum care. We're thrilled to partner with Ema to offer moms personalized information along this journey," adds Sarah O'Leary, CEO of Willow. "AI tools, when implemented thoughtfully, can help close gaps in delivering personalized guidance at an efficient scale and I'm excited about the impact Ema can have on the well-being of mothers in our Willow community."

Founded in 2018 as a way to connect new moms, Ema evolved with a major rebrand and pivot to AI-backed tools last year.

Willow was launched in 2014 and released the first wearable, in-bra breast pump in 2017.

Houston researchers find alternate data for loan qualification

houston voices

Millions of consumers who apply for a loan to buy a house or car or start a business can’t qualify — even if they’re likely to pay it back. That’s because many lack a key piece of financial information: a credit score.

The problem isn’t just isolated to emerging economies. Exclusion from the financial system is a major issue in the United States, too, where some 45 million adults may be denied access to loans because they don’t have a credit history and are “credit invisible.”

To improve access to loans and peoples’ economic mobility, lenders have started looking into alternative data sources to assess a loan applicant’s risk of defaulting. These include bank account transactions and on-time rental, utility and mobile phone payments.

A new article by Rice Business assistant professor of marketing Jung Youn Lee and colleagues from Notre Dame and Northwestern identifies an even more widespread data source that could broaden the pool of qualified applicants: grocery store receipts.

As metrics for predicting credit risk, the researchers found that the types of food, drinks and other products consumers buy, and how they buy them, are just as good as a traditional credit score.

“There could be privacy concerns when you think about it in practice,” Lee says, “so the consumer should really have the option and be empowered to do it.” One approach could be to let consumers opt in to a lender looking at their grocery data as a second chance at approval rather than automatically enrolling them and offering an opt-out.

To arrive at their findings, the researchers analyzed grocery transaction data from a multinational conglomerate headquartered in a Middle Eastern country that owns a credit card issuer and a large-scale supermarket chain. Many people in the country are unbanked. They merged the supermarket’s loyalty card data and issuer’s credit card spending and payment history numbers, resulting in data on 30,089 consumers from January 2017 to June 2019. About half had a credit score, 81% always paid their credit card bills on time, 12% missed payments periodically, and 7% defaulted.

The researchers first created a model to establish a connection between grocery purchasing behavior and credit risk. They found that people who bought healthy foods like fresh milk, yogurt and fruits and vegetables were more likely to pay their bills on time, while shoppers who purchased cigarettes, energy drinks and canned meat tended to miss payments. This held true for “observationally equivalent” individuals — those with similar income, occupation, employment status and number of dependents. In other words, when two people look demographically identical, the study still finds that they have different credit risks.

People’s grocery-buying behaviors play a factor in their likelihood to pay their bills on time, too. For example, cardholders who consistently paid their credit card bill on time were more likely to shop on the same day of the week, spend similar amounts across months and buy the same brands and product categories.

The researchers then built two credit-scoring predictive algorithms to simulate a lender’s decision of whether or not to approve a credit card applicant. One excludes grocery data inputs, and the other includes them (in addition to standard data). Incorporating grocery data into their decision-making process improved risk assessment of an applicant by a factor of 3.11% to 7.66%.

Furthermore, the lender in the simulation experienced a 1.46% profit increase when the researchers implemented a two-stage decision-making process — first, screening applicants using only standard data, then adding grocery data as an additional layer.

One caveat to these findings, Lee and her colleagues warn, is that the benefit of grocery data falls sharply as traditional credit scores or relationship-specific credit histories become available. This suggests the data could be most helpful for consumers new to credit.

Overall, however, this could be a win-win scenario for both consumers and lenders. “People excluded from the traditional credit system gain access to loans,” Lee says, “and lenders become more profitable by approving more creditworthy people.”